[go: up one dir, main page]

WO1998039436A3 - Compositions de muteine du facteur de croissance des fibroblastes, et procedes d'utilisation de ces compositions - Google Patents

Compositions de muteine du facteur de croissance des fibroblastes, et procedes d'utilisation de ces compositions Download PDF

Info

Publication number
WO1998039436A3
WO1998039436A3 PCT/JP1998/000878 JP9800878W WO9839436A3 WO 1998039436 A3 WO1998039436 A3 WO 1998039436A3 JP 9800878 W JP9800878 W JP 9800878W WO 9839436 A3 WO9839436 A3 WO 9839436A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
growth factor
fibroblast growth
fgf
use therefor
Prior art date
Application number
PCT/JP1998/000878
Other languages
English (en)
Other versions
WO1998039436A2 (fr
Inventor
Hengyi Zhu
Ramnarayan Kalyanaraman
Takatoshi Kawai
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of WO1998039436A2 publication Critical patent/WO1998039436A2/fr
Publication of WO1998039436A3 publication Critical patent/WO1998039436A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention décrit des mollécules d'ADN isolées qui codent des polypeptides de mutéine du facteur de croissance de fibroblaste (FCF) ainsi que les mutéines FCF codées. Les mutéines FCF présentent une activité de liaison de récepteur réduite mais gardent leur aptitude à se fixer à l'héparine. Des procédés de traitement de troubles liés à l'héparine consistent à administrer une quantité thérapeutiquement efficace d'une mutéine FCF.
PCT/JP1998/000878 1997-03-03 1998-03-03 Compositions de muteine du facteur de croissance des fibroblastes, et procedes d'utilisation de ces compositions WO1998039436A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4078597P 1997-03-03 1997-03-03
US60/040,785 1997-03-03

Publications (2)

Publication Number Publication Date
WO1998039436A2 WO1998039436A2 (fr) 1998-09-11
WO1998039436A3 true WO1998039436A3 (fr) 1999-01-14

Family

ID=21912937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/000878 WO1998039436A2 (fr) 1997-03-03 1998-03-03 Compositions de muteine du facteur de croissance des fibroblastes, et procedes d'utilisation de ces compositions

Country Status (1)

Country Link
WO (1) WO1998039436A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020189A (en) 1996-08-30 2000-02-01 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factors (FHFs) and methods of use
US7252818B2 (en) 1998-07-24 2007-08-07 Cardiovascular Biotherapeutics, Inc. Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
WO2002014471A2 (fr) * 2000-08-15 2002-02-21 Phage Biotechnology Corporation Procede de production du facteur de croissance de fibroblastes humain acide biologiquement actif et son utilisation pour favoriser l'angiogenese
AU2002355844A1 (en) * 2001-08-01 2003-02-17 New York University Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022369A1 (fr) * 1994-10-13 1996-07-25 Amgen Inc. Analogues de facteur de croissance du fibroblaste acide a stabilite et activite biologique renforcees
WO1996038167A1 (fr) * 1995-05-31 1996-12-05 Osteosa, Inc. Utilisation de facteurs de croissance des fibroblastes pour stimuler la croissance osseuse

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022369A1 (fr) * 1994-10-13 1996-07-25 Amgen Inc. Analogues de facteur de croissance du fibroblaste acide a stabilite et activite biologique renforcees
WO1996038167A1 (fr) * 1995-05-31 1996-12-05 Osteosa, Inc. Utilisation de facteurs de croissance des fibroblastes pour stimuler la croissance osseuse

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURGESS, W.H., ET AL.: "possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic Fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue", THE JOURNAL OF CELL BIOLOGY, vol. 111, November 1990 (1990-11-01), pages 2129 - 2138, XP002074068 *
SPRINGER, B.A., ET AL.: "identification and concerted function of two receptor binding surfaces on basic fibroblast growth factor required for mitogenesis", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 43, October 1994 (1994-10-01), pages 26879 - 26884, XP002073992 *
WANG W -P ET AL: "CLONING OF THE GENE CODING FOR HUMAN CLASS 1 HEPARIN-BINDING GROWTH FACTOR AND ITS EXPRESSION IN FETAL TISSUES", MOLECULAR AND CELLULAR BIOLOGY, vol. 9, no. 6, June 1989 (1989-06-01), pages 2387 - 2395, XP000039606 *
ZHU, H., ET AL.: "Glu-96 of basic fibroblast growth factor is essential for high affinity receptor binding", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 37, September 1995 (1995-09-01), pages 21869 - 21874, XP002073993 *

Also Published As

Publication number Publication date
WO1998039436A2 (fr) 1998-09-11

Similar Documents

Publication Publication Date Title
WO2002030358A3 (fr) Modulation de fonction de ccr4
CA2269083A1 (fr) Homologues de facteur de croissance fibroblastes (fgf)
CA2290520A1 (fr) Inhibition de l'activite de la p38 kinase par des aryl-urees
HUP0003280A3 (en) Peptides having apolipoprotein a-1 agonist activity, pharmaceutical compositions comprising thereof and their use to treat dyslipidemic disorders
WO2001016114A3 (fr) Composes et techniques permettant de moduler la fonction du recepteur cxcr3
WO1992013553A3 (fr) Procede et agents favorisant la cicatrisation
CA2296769A1 (fr) Facteur modifie affectant le tissu dorsal et composition a base de ce facteur
TR199802421T2 (xx) Doku yenilenmesini d�zenleyen maddeler.
CA2312667A1 (fr) Nouvelle cytokine
WO2000001815A3 (fr) Facteurs neurotrophiques
EP0637450A3 (fr) Méthode et composition pour revigorer le tissu cicatriciel.
WO2000025725A3 (fr) Antagonistes fonctionnels de l'activite hedgehog
MY104992A (en) Composition inducing a binding.
WO1999029729A3 (fr) Fonction et utilisation de l'antagoniste du recepteur de la neuropiline
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
WO1999055861A3 (fr) Compositions de muteine du facteur de croissance de fibroblastes et procedes d'utilisation associes
AU1934995A (en) Receptor specific atrial natriuretic peptides
CA2233009A1 (fr) Composition pour ameliorer la fonction pancreatique
FI972703L (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
CA2255539A1 (fr) Utilisations therapeutiques de produits proteiques bpi chez des patients humains souffrant d'une hemorragie causee par un traumatisme
WO2002030357A3 (fr) Composes et procedes servant a moduler la fonction de ccr4
WO2000053749A3 (fr) Molecules d'adhesion vasculaire et modulation de leur fonction
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
AU5283890A (en) Fibroblast growth factor (fgf)-based stabilized compositions
WO1998039436A3 (fr) Compositions de muteine du facteur de croissance des fibroblastes, et procedes d'utilisation de ces compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998538364

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase